Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for shareholders to make money if they buy a good busines ...

The latest update is out from Inmune Bio ( (INMB) ).

INmune Bio Contact: David Moss, CFO (858) 964-3720 info@inmunebio.com Investor Contact: Jason Nelson Core IR (516) 842-9614 x-823 ...

Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio’s XPro to yield impressive results in its phase 2 trials like ...

INmune Bio's XPro is probably the most-promising drug candidate in the history of neurodegenerative diseases. INMB’s share price just dropped at an all-time low due to a US-related clinical hold ...

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, ...

INmune Bio Inc. announced results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF inhibitor, for early Alzheimer's Disease (AD) in patients showing inflammation biomarkers.

INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.com Investor Contact:James Carbonara Hayden IR (646)-755-7412 james@haydenir.com ...